160 related articles for article (PubMed ID: 33475035)
1. Screening for
Al-Qahtani WS; Alduwish MA; Al-Olayan EM; Aljarba NH; Em AH; Albani FG; Domiaty DM; Al-Otaibi AM; Qattan SMA; Almurshedi AS; Elasbali AM; Ahmed HG; Almutlaq BA
J Obstet Gynaecol; 2021 Oct; 41(7):1127-1133. PubMed ID: 33475035
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
[TBL] [Abstract][Full Text] [Related]
4. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.
Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR
Am J Pathol; 2013 Apr; 182(4):1391-9. PubMed ID: 23499052
[TBL] [Abstract][Full Text] [Related]
5. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
Zhang Z; Zhang L; Wang B; Wei R; Wang Y; Wan J; Zhang C; Zhao L; Zhu X; Zhang Y; Chu C; Guo Q; Yin X; Li X
Cancer Lett; 2020 Jan; 469():54-67. PubMed ID: 31629932
[TBL] [Abstract][Full Text] [Related]
6. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Levine DA; Bogomolniy F; Yee CJ; Lash A; Barakat RR; Borgen PI; Boyd J
Clin Cancer Res; 2005 Apr; 11(8):2875-8. PubMed ID: 15837735
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
12. Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.
Chen H; Zhai Z; Xie Q; Lai Y; Chen G
J Assist Reprod Genet; 2021 Oct; 38(10):2631-2639. PubMed ID: 33834328
[TBL] [Abstract][Full Text] [Related]
13. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract][Full Text] [Related]
14. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
Nodin B; Zendehrokh N; Sundström M; Jirström K
Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
[TBL] [Abstract][Full Text] [Related]
16. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in advanced ovarian carcinomas.
Wang Y; Helland A; Holm R; Kristensen GB; Børresen-Dale AL
Hum Mutat; 2005 Mar; 25(3):322. PubMed ID: 15712344
[TBL] [Abstract][Full Text] [Related]
19. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
